Imiquimod 5% cream (Aldara(TM))

Expert Opinion on Investigational Drugs

Volumn 7, Issue 3, 1998, Pages 437-449

  Slade, H B ^a   Owens, M L ^a   Tomai, M A ^a   Miller, R L ^a  

^a 3M COMPANY   (United States)

Author keywords

Adjuvants; Aldara; Aminoquinolines; Biological response modifiers; Bladder neoplasms; Clinical trial; Condylomata acuminata; Cytokines; Imiquimod; Immune deviation; Immunological; Immunostimulants; Immunotherapy; Interferon inducers; Interferons; Papillomavirus

Indexed keywords

CYTOKINE; DRUG METABOLITE; IMIQUIMOD; INTERFERON INDUCING AGENT; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; POLYINOSINIC POLYCYTIDYLIC ACID; S 26704; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

CELL LINE; CONDYLOMA; DOSE RESPONSE; DRUG SAFETY; ERYTHEMA; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; INTERFERON INDUCTION; KERATINOCYTE; MONONUCLEAR CELL; PAIN; PHOTOALLERGY; POLYMERASE CHAIN REACTION; PRURITUS; REGISTRATION; SEX DIFFERENCE; SHORT SURVEY; SKIN EDEMA; SKIN IRRITATION; VERRUCA VULGARIS; WART VIRUS;

EID: 0031881818     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.7.3.437     Document Type: Short Survey

References (28)